Cipla: Focus shifts to FY23 launches
In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch
Ami Organics: What should investors do, post recent correction?
According to the management of Ami Organics, the priority for the acquired business of Gujarat Organics is to stabilise revenue and focus on reducing inefficiencies
Gland Pharma: Operating leverage to offset input cost pain
As far as geographical diversification is concerned, Gland Pharma's foray into non-US markets is expected to accelerate. It's seen to leverage from products already approved in the US for launch in other markets
Syngene: Look beyond the near-term input cost pressure
Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22
Navin Fluorine: Should investors accumulate the stock, post recent correction?
Recent initiatives present a significant opportunity as Navin continues to invest in talent and technology and get new inquiries from innovators
What should investors do with this diagnostic play as COVID cases drop?
Krsnaa Diagnostics presents superior contract execution and scalability in radiology diagnostics
Food colour companies are in capacity overdrive. What next for investors?
Indian food colour industry is set for dominance after the sharp scale-up in capacity expansion and end-market expertise. Vidhi specialty remains our preferred play
China supply crisis: Can India’s chemicals step in?
In the last 20 months, COVID, logistics issues, and, now, power shortages have accelerated the global trend of de-risking the supply chain from China which would benefit the entire Indian chemical industry.
How does the power crunch in China play out for Indian sectors?
China power outages is likely to keep prices of commodities at elevated levels; China-plus theme gets further push
For Sumitomo Chemicals India, speciality is the trump card
The key near-term trigger for Sumitomo Chemical is the manufacturing of technical grade active ingredients for its parent company
Fine Organics glued to green chemicals, may keep valuation premium
The medium-term growth in earnings for Fine Organics is expected to be driven mainly by volume growth in new capacities, better realisations and normalisation of input costs
Fed signals early taper, but there is no immediate impact
The Fed continues to delink interest rate lift-off from tapering. Though the dot-plot of the September meeting hints towards one rate hike of 25 bps in 2022, Powell said “lift-off in policy rates” is not on its radar, as of now
Ami Organics: Is it time to book profit as strong listing narrows valuation gap?
Post the strong listing, multiples are close to some of the larger players in chemicals, having their end-market as pharma.
Vijaya Diagnostic: What does this regional player offer amid industry consolidation?
Going forward, technology will be the differentiator, and Vijay Diagnostic's differentiated hub- and-spoke model calls for attention
SRF: Growth casts its net wide, but margins face pressure
The EBITDA margins of SRF are likely to moderate as the benefit from the operating leverage gets blunted by the margin contraction in the packaging business
What's the trump card for this speciality chemical player?
Recent developments point to Clean Science and Technology's focus on enlarging product basket and a focus on green chemistry, which helps it differentiate from the rest
Ami Organics IPO: A play on critical pharma intermediates
Intermediates are the key area where import dependence is huge, and, hence, a company like Ami Organics is likely to benefit
Vijaya Diagnostic IPO: Can this regional player repeat the success of KIMS IPO?
The key strength of Vijaya Diagnostic lies in its heavy B2C mix – more than 90 per cent of business flows from individual customers. This ensures that the company has almost negligible receivables which helps it to maintain a negative working capital.
Divi’s Labs: Green chemistry gives it the upper hand
Divi's Labs has a strong focus on ‘green chemistry’, helping it to reduce wastage through technology adoption, leading to better profitability and relationship with global clients
For NOCIL, demand pick-up, 'China plus' spell good news
On the exports front, enquiries from new customers have increased as MNC clients want to contain the China supply-chain risk
Cadila: Vaccine opportunity unfolds
On conservative basis, for COVID vaccine opportunity, Cadila can at least add 16 per cent of FY21 sales revenue, on a full-year basis
Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries
We believe termination of the Cronus Pharma acquisition deal should help remove corporate governance/capital allocation fears
Suven Pharma: Normalisation of margins adds to comfort
There is an emerging preference for full-service CDMOs. This puts players like Suven in a better spot as it tries to capture the whole of the value chain
Aurobindo Pharma: Value proposition intact, but consolidation can take longer
In this injectables space, Aurobindo pharma remains constructive and plans to grow from the current annual sales base of $400 million to 650-700 million in three years, backed by new plants in the US and Vizag.
- Budget 2022: Commodity markets ask for CTT waiver with volumes on a constant decline Watch more
- Ideas For Profit | Why Federal Bank is a favourite among mid-cap banking stocks Watch more
- Sterling and Wilson presents Energizing India in association with Moneycontrol Watch more
- Budget 2022: Investors want higher infra capex, LTCG & dividend distribution tax & more Watch more